L'Oréal's increased investment in Galderma reinforces the aesthetics company's position and may accelerate product launches.
L'Oréal has raised its ownership stake in Galderma to 20%, deepening its strategic partnership with the Swiss-based aesthetics and dermatology company. This move underscores L'Oréal's commitment to the medical-aesthetics market and suggests confidence in Galderma's pipeline, including relabotulinum and other injectables.
L'Oréal's backing provides capital, distribution leverage, and brand-building resources that can accelerate Galderma's market penetration in the U.S. medspa channel. The increased stake also signals that L'Oréal views medical aesthetics as a core growth vector—a position that mirrors AbbVie's acquisition of Allergan and Estée Lauder's stake in Revance. Consolidation of beauty conglomerates into medical aesthetics is reshaping competitive dynamics and loyalty economics.
L'Oréal's 20% stake signals the beauty industry's long-term bet on medical aesthetics as a core growth engine.
For practices, L'Oréal's deeper involvement may translate to more aggressive marketing, expanded rebate programs, and bundled offerings across Galderma's toxin, filler, and device portfolios—particularly if relabotulinum gains FDA approval.
Source: original report ↗
Free alerts Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo Join the owners who run ahead of the industry. Cancel anytime, one click.
